Stephen Simes
Director/Board Member chez CYTODYN INC.
Fortune : - $ au 31/03/2024
Profil
Stephen M.
Simes is currently the Chairman of Bio-Xl Ltd.
and an Independent Director of CytoDyn, Inc. and Biolife4d Corp.
He previously served as the President, CEO, and Director of Unimed Pharmaceuticals LLC, Vice Chairman, President, and CEO of ANI Pharmaceuticals, Inc., and Chairman, President, and CEO of Gynex Pharmaceuticals, Inc. He was also the CEO and Director of RestorGenex Corp.
and the Chief Executive Officer of Diffusion Pharmaceuticals, Inc. Additionally, he served as a Director and Senior Vice President of Savient Pharmaceuticals, Inc. and a Director of Ceregene, Inc. He was an Independent Director of SciSparc Ltd.
from 2016 to 2020.
He started his career as a Principal at G.D.
Searle & Co., Inc. Simes received his undergraduate degree from Brooklyn College and his MBA from New York University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CYTODYN INC.
-.--% | 03/01/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Stephen Simes
| Sociétés | Poste | Début |
|---|---|---|
| CYTODYN INC. | Director/Board Member | 13/10/2022 |
Biolife4d Corp.
 Biolife4d Corp. BiotechnologyHealth Technology Biolife4d Corp. engages in biotechnology services. It focuses on leveraging advances in life sciences and tissue engineering to three-dimensional bioprint a viable human heart suitable for transplant. The company was founded by Steven Morris on November 14, 2016 and is headquartered in Buffalo Grove, IL. | Director/Board Member | 04/02/2022 |
| Bio-Xl Ltd. | Chairman | - |
Anciens postes connus de Stephen Simes
| Sociétés | Poste | Fin |
|---|---|---|
| SCISPARC LTD. | Director/Board Member | 21/08/2020 |
RestorGenex Corp.
 RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | Chief Executive Officer | 08/01/2016 |
| ANI PHARMACEUTICALS, INC. | President | 19/06/2013 |
Ceregene, Inc.
 Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | Director/Board Member | 01/01/2013 |
Unimed Pharmaceuticals LLC
 Unimed Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Unimed Pharmaceuticals, Inc. manufactured pharmaceutical products. It provided multiple indications in the therapeutic areas of cardiology, men's health, HIV and other infectious diseases. The company was founded in 1999 and was headquartered in Marietta, GA. | Chief Executive Officer | 01/01/1997 |
Formation de Stephen Simes
| Brooklyn College | Undergraduate Degree |
| New York University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ANI PHARMACEUTICALS, INC. | Health Technology |
| CYTODYN INC. | Health Technology |
| SCISPARC LTD. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
Unimed Pharmaceuticals LLC
Unimed Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Unimed Pharmaceuticals, Inc. manufactured pharmaceutical products. It provided multiple indications in the therapeutic areas of cardiology, men's health, HIV and other infectious diseases. The company was founded in 1999 and was headquartered in Marietta, GA. | Health Technology |
Ceregene, Inc.
Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | Health Technology |
G.D. Searle & Co., Inc.
 G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | Process Industries |
Gynex Pharmaceuticals, Inc.
 Gynex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Gynex Pharmaceuticals, Inc. is a pharmaceutical concern. The private company is based in Vernon Hills, IL. Gynex Pharmaceuticals was acquired by Savient Pharmaceuticals, Inc. on August 09, 1993 for $47.87 million. | Health Technology |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | Health Technology |
Diffusion Pharmaceuticals, Inc.
 Diffusion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing novel therapies that enhance the body's ability to deliver oxygen. The firm's product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA. | Health Technology |
Biolife4d Corp.
Biolife4d Corp. BiotechnologyHealth Technology Biolife4d Corp. engages in biotechnology services. It focuses on leveraging advances in life sciences and tissue engineering to three-dimensional bioprint a viable human heart suitable for transplant. The company was founded by Steven Morris on November 14, 2016 and is headquartered in Buffalo Grove, IL. | Health Technology |
| Bio-Xl Ltd. |
